CEACAM1 and acute myeloid leukemia: In the 18 hub genes, CEACAM1, CRISP2, and CYP4F3 showed their strong competitiveness in both expression analyses (AML PB samples vs. healthy blood samples and AML BM samples posttreatment stage vs. diagnosis/recurrent stages) and the survival analysis.